Carpén O - Search Results

1

Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative.

Cuppens T, Annibali D, Coosemans A, Trovik J, Ter Haar N, Colas E, Garcia-Jimenez A, Van de Vijver K, Kruitwagen RP, Brinkhuis M, Zikan M, Dundr P, Huvila J, Carpén O, Haybaeck J, Moinfar F, Salvesen HB, Stukan M, Mestdagh C, Zweemer RP, Massuger LF, Mallmann MR, Wardelmann E, Mints M, Verbist G, Thomas D, Gommé E, Hermans E, Moerman P, Bosse T, Amant F. Cuppens T, et al. Among authors: carpen o. Clin Cancer Res. 2017 Mar 1;23(5):1274-1285. doi: 10.1158/1078-0432.CCR-16-2149. Clin Cancer Res. 2017. PMID: 28232476

2

Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.

Huvila J, Talve L, Carpén O, Edqvist PH, Pontén F, Grénman S, Auranen A. Huvila J, et al. Among authors: carpen o. Gynecol Oncol. 2013 Sep;130(3):463-9. doi: 10.1016/j.ygyno.2013.06.015. Epub 2013 Jun 15. Gynecol Oncol. 2013. PMID: 23777659

3

Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma.

Edqvist PH, Huvila J, Forsström B, Talve L, Carpén O, Salvesen HB, Krakstad C, Grénman S, Johannesson H, Ljungqvist O, Uhlén M, Pontén F, Auranen A. Edqvist PH, et al. Among authors: carpen o. Gynecol Oncol. 2015 Jun;137(3):529-37. doi: 10.1016/j.ygyno.2015.03.055. Epub 2015 Apr 7. Gynecol Oncol. 2015. PMID: 25858696

4

Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.

Chen P, Huhtinen K, Kaipio K, Mikkonen P, Aittomäki V, Lindell R, Hynninen J, Auranen A, Grénman S, Lehtonen R, Carpén O, Hautaniemi S. Chen P, et al. Among authors: carpen o. Cancer Res. 2015 Aug 1;75(15):2987-98. doi: 10.1158/0008-5472.CAN-14-3242. Epub 2015 Jun 29. Cancer Res. 2015. PMID: 26122843 Clinical Trial.

5

Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways.

Cuppens T, Moisse M, Depreeuw J, Annibali D, Colas E, Gil-Moreno A, Huvila J, Carpén O, Zikán M, Matias-Guiu X, Moerman P, Croce S, Lambrechts D, Amant F. Cuppens T, et al. Among authors: carpen o. Int J Cancer. 2018 Mar 15;142(6):1230-1243. doi: 10.1002/ijc.31129. Epub 2017 Nov 7. Int J Cancer. 2018. PMID: 29063609 Free article.

6

Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma.

Huvila J, Laajala TD, Edqvist PH, Mardinoglu A, Talve L, Pontén F, Grénman S, Carpén O, Aittokallio T, Auranen A. Huvila J, et al. Among authors: carpen o. Gynecol Oncol. 2018 Apr;149(1):173-180. doi: 10.1016/j.ygyno.2018.02.016. Epub 2018 Mar 2. Gynecol Oncol. 2018. PMID: 29486992

7

Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes.

Pikkusaari S, Tumiati M, Virtanen A, Oikkonen J, Li Y, Perez-Villatoro F, Muranen T, Salko M, Huhtinen K, Kanerva A, Koskela H, Tapper J, Koivisto-Korander R, Joutsiniemi T, Haltia UM, Lassus H, Hautaniemi S, Färkkilä A, Hynninen J, Hietanen S, Carpén O, Kauppi L. Pikkusaari S, et al. Among authors: carpen o. Clin Cancer Res. 2023 Aug 15;29(16):3110-3123. doi: 10.1158/1078-0432.CCR-22-3156. Clin Cancer Res. 2023. PMID: 36805632 Free PMC article.

8

Ezrin is key regulator of Src-induced malignant phenotype in three-dimensional environment.

Heiska L, Melikova M, Zhao F, Saotome I, McClatchey AI, Carpén O. Heiska L, et al. Among authors: carpen o. Oncogene. 2011 Dec 15;30(50):4953-62. doi: 10.1038/onc.2011.207. Epub 2011 Jun 13. Oncogene. 2011. PMID: 21666723

9

EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus.

Birkman EM, Ålgars A, Lintunen M, Ristamäki R, Sundström J, Carpén O. Birkman EM, et al. Among authors: carpen o. BMC Cancer. 2016 Jul 7;16:406. doi: 10.1186/s12885-016-2456-1. BMC Cancer. 2016. PMID: 27387915 Free PMC article.

10

Mathematical Modeling Predicts Response to Chemotherapy and Drug Combinations in Ovarian Cancer.

Kozłowska E, Färkkilä A, Vallius T, Carpén O, Kemppainen J, Grénman S, Lehtonen R, Hynninen J, Hietanen S, Hautaniemi S. Kozłowska E, et al. Among authors: carpen o. Cancer Res. 2018 Jul 15;78(14):4036-4044. doi: 10.1158/0008-5472.CAN-17-3746. Epub 2018 May 16. Cancer Res. 2018. PMID: 29769198

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

266 results

Search Page